Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pieris Pharmaceuticals ( (PIRS) ) has shared an announcement.
Pieris Pharmaceuticals announced the approval of several key proposals during a special stockholder meeting, including a significant increase in authorized shares from 3,750,000 to 200,000,000, and the approval of the 2024 Equity Incentive Plan. Additionally, the company finalized plans for a merger with Palvella Therapeutics, which will result in a name change to Palvella Therapeutics, Inc., potentially enhancing its market positioning and operational capabilities.
More about Pieris Pharmaceuticals
Pieris Pharmaceuticals operates in the biotechnology industry, focusing on the development of therapeutic proteins for various medical conditions.
YTD Price Performance: 14.01%
Average Trading Volume: 20,126
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $21.92M
Learn more about PIRS stock on TipRanks’ Stock Analysis page.